Novo Nordisk A/S ADR

Several cases can be made for buying what seem to be fairly valued high-quality stocks.

One company was awarded a moat last month while a few others experienced fair value increases of 10% of more.

Silver-rated Loomis Sayles Growth's patient approach to growth investing and reasonable fees have generated fine risk-adjusted results.

Better standards align manager incentives with shareholder interests.

The firm's key program for treating NASH is well positioned, but the space is becoming increasingly crowded.

Alphabet, Visa, and Novo Nordisk outperformed, while energy and basic materials were a drag on returns, says Morningstar's Matt Coffina.

The newly independent firm still has a narrow moat, however.

Small growth and biotech exposure led, while large value lagged.

The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

From moats to fair value to stewardship, we explain the key pillars of our approach to equities.

These managers are potential contenders for this year's honor.

Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

Recent M&A activity among health-care stocks indicates firms are homing in on core competencies and cost savings, but stock-buying ideas remain unclear.

These firms are leaders in the insulin market and are positioned to bring next-generation blockbusters to market.

Several pharma firms are taking the lead on drugs to fight the disease.

Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

Roundtable Report: At the outset of 2014, Morningstar strategists dig into the market's current valuation and expected return, seek out high-quality U.S. and foreign stock opportunities, size up the role of cash today, assess the Fed's impact on the market, and reveal the best ways to fight inflation.

The diversified health-care firm remains remarkably profitable in tough industries.

Despite the rollout complications, the Affordable Care Act will affect health-care subsectors differently but won't have much of an impact on stocks overall, says StockInvestor editor Matt Coffina.